Top

Published in:

Open Access 01-03-2013 | Letter to the Editors

The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia

Authors: Grant Guthrie, Gerald Pfeffer, Maura Bailie, Karen Bradshaw, Andrew C. Browning, Rita Horvath, Patrick F. Chinnery, Patrick Yu-Wai-Man

Published in: Journal of Neurology | Issue 3/2013

Excerpt

Dear Sirs, …

Available only for authorised users

Salinas S, Proukakis C, Crosby A, Warner TT (2008) Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 7:1127–1138PubMedCrossRef

Harding AE (1983) Classification of the hereditary ataxias and paraplegias. Lancet 1:1151–1155PubMedCrossRef

McDermott CJ, Grierson AJ, Wood JD et al (2003) Hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation. Ann Neurol 54:748–759PubMedCrossRef

Lumb JH, Connell JW, Allison R, Reid E (2012) The AAA ATPase spastin links microtubule severing to membrane modelling. Biochim Biophys Acta 1823:192–197PubMedCrossRef

Schon EA, Przedborski S (2011) Mitochondria: the next (Neurode) generation. Neuron 70:1033–1053PubMedCrossRef

Yu-Wai-Man P, Griffiths PG, Gorman GS et al (2010) Multi-system neurological disease is common in patients with OPA1 mutations. Brain 133:771–786PubMedCrossRef

Baker MR, Fisher KM, Whittaker RG, Griffiths PG, Yu-Wai-Man P, Chinnery PF (2011) Subclinical multisystem neurologic disease in “pure” Opa1 autosomal dominant optic atrophy. Neurology 77:1309–1312PubMedCrossRef

Casari G, De Fusco M, Ciarmatori S et al (1998) Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93:973–983PubMedCrossRef

Wilkinson PA, Crosby AH, Turner C et al (2004) A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain 127:973–980PubMedCrossRef

10.

van Gassen KL, van der Heijden CD, de Bot ST et al (2012) Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort. Brain 135:2994–3004PubMedCrossRef

11.

Tallaksen CME, Guichart-Gomez E, Verpillat P et al (2003) Subtle cognitive impairment but no dementia in patients with spastin mutations. Arch Neurol 60:1113–1118PubMedCrossRef

12.

McMonagle P, Byrne P, Hutchinson M (2004) Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. Neurology 62:407–410PubMedCrossRef

13.

Murphy S, Gorman G, Beetz C et al (2009) Dementia in SPG4 hereditary spastic paraplegia Clinical, genetic, and neuropathologic evidence. Neurology 73:378–384PubMedCrossRef

14.

Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMedCrossRef

15.

Watson M (2002) Refining the ten-metre walking test for use with neurologically impaired people. Physiotherapy 88:386–397CrossRef

Title: The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia
Authors: Grant Guthrie
Gerald Pfeffer
Maura Bailie
Karen Bradshaw
Andrew C. Browning
Rita Horvath
Patrick F. Chinnery
Patrick Yu-Wai-Man
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 3/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6780-3

At a glance: The STEP trials

Springer Medicine

The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2013

Pregnancy in congenital myasthenic syndrome

Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study

Communications of the European Neurological Society

Effects of cerebellar infarcts on cortical processing of saccades

Multiple sclerosis imaging: recent advances

A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network